RARA CRAFT DATABASE for FDA Medical Devices
De NovoDEN220066

FDA DEVICE FACTS

BrainSee

Darmiyan, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

AI/ML
DECISION DATE01/11/2024PRODUCT CODEQWT

Indications for use

“BrainSee is a software application indicated as a prognostic tool to aid in the clinical assessment of how likely patients aged between 55 and 95 years old who are diagnosed with amnestic mild cognitive impairment (aMCI) are to progress to clinical Alzheimer’s disease (AD)-dementia within 5 years of assessment. BrainSee analyzes inputs of brain magnetic resonance imaging (MRI), patient demographic information, and cognitive assessment scores to produce a similarity score between 0 and 100 reflecting the degree of similarity between the patient and two reference populations of aMCI patients who either did not progress to clinical AD-dementia within 5 years (non-converters) or progressed to clinical AD-dementia within 5 years (converters). Clinical AD-dementia is defined as probable Alzheimer’s disease established according to the National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer’s Criteria.

• Similarity scores less than 50 indicate that a patient’s inputs are more similar to those of the non-converter population.

• Similarity scores greater than 50 indicate that a patient’s inputs are more similar to those of the converter population.

• Patients with a similarity score close to 50 have inputs that are similar to both the converter and non-converter aMCI patient populations used to develop and train the BrainSee device. The similarity score output is provided along with information to assist in the interpretation of the output to aid in evaluating the prognosis of patients diagnosed with aMCI to progress to clinical AD-dementia within 5 years. The BrainSee analysis is intended to provide supplemental information for interpretation in conjunction with a standard neurological assessment. Patient management decisions should not be made solely on the results of the BrainSee analysis. BrainSee is not indicated as a stand-alone diagnostic or prognostic tool. BrainSee should not be used to diagnose aMCI.”

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026